Literature DB >> 11314751

Management of thyroglobulin positive/whole-body scan negative: is Tg positive/131I therapy useful?

I R McDougall1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11314751     DOI： 10.1007/BF03343843

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  13 in total

1.  Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients.

Authors:  H R Maxon; E E Englaro; S R Thomas; V S Hertzberg; J D Hinnefeld; L S Chen; H Smith; D Cummings; M D Aden
Journal:  J Nucl Med       Date:  1992-06       Impact factor: 10.057

2.  Staging in thyroid carcinoma.

Authors:  B Cady
Journal:  Cancer       Date:  1998-09-01       Impact factor: 6.860

3.  74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer.

Authors:  I R McDougall
Journal:  Nucl Med Commun       Date:  1997-06       Impact factor: 1.690

4.  Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma.

Authors:  P W Ladenson; L E Braverman; E L Mazzaferri; F Brucker-Davis; D S Cooper; J R Garber; F E Wondisford; T F Davies; L J DeGroot; G H Daniels; D S Ross; B D Weintraub
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

5.  Treatment of micronodular lung metastases of papillary thyroid cancer: are the tumors too small for effective irradiation from radioiodine?

Authors:  J C Sisson; D A Jamadar; E A Kazerooni; T J Giordano; J E Carey; S A Spaulding
Journal:  Thyroid       Date:  1998-03       Impact factor: 6.568

6.  Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels.

Authors:  F Pacini; F Lippi; N Formica; R Elisei; S Anelli; C Ceccarelli; A Pinchera
Journal:  J Nucl Med       Date:  1987-12       Impact factor: 10.057

7.  Follow-up of patients with differentiated thyroid cancer using serum thyroglobulin measured by an immunoradiometric assay. Comparison with I-131 total body scans.

Authors:  I R McDougall; M F Bayer
Journal:  J Nucl Med       Date:  1980-08       Impact factor: 10.057

8.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

9.  Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131.

Authors:  H M Park; O W Perkins; J W Edmondson; R B Schnute; A Manatunga
Journal:  Thyroid       Date:  1994       Impact factor: 6.568

10.  Comparison of 30- and 50-mCi doses of iodine-131 for thyroid ablation.

Authors:  L J Degroot; M Reilly
Journal:  Ann Intern Med       Date:  1982-01       Impact factor: 25.391
View more
  2 in total

1.  Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.

Authors:  A S Alzahrani; G Mohamed; A Al Shammary; S Aldasouqi; S Abdal Salam; M Shoukri
Journal:  J Endocrinol Invest       Date:  2005-06       Impact factor: 4.256

2.  Preoperative neck ultrasonographic mapping for persistent/recurrent papillary thyroid cancer.

Authors:  Hussam M Binyousef; Ali S Alzahrani; Saif S Al-Sobhi; Suhaibani Hamed S Al; Mohammed A Chaudhari; Hussain M Raef
Journal:  World J Surg       Date:  2004-11       Impact factor: 3.352
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.